Van ECK Associates Corp Acquires 120,127 Shares of Novo Nordisk A/S $NVO

Van ECK Associates Corp boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 18.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 788,722 shares of the company’s stock after acquiring an additional 120,127 shares during the period. Van ECK Associates Corp’s holdings in Novo Nordisk A/S were worth $43,766,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the stock. True Wealth Design LLC grew its stake in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the period. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S in the third quarter valued at about $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S during the third quarter worth about $30,000. Allianz SE boosted its holdings in Novo Nordisk A/S by 70.0% during the third quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after buying an additional 238 shares during the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth about $39,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of a number of analyst reports. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Citigroup assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating for the company. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Finally, Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday. Four investment analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $49.93.

Novo Nordisk A/S Trading Up 0.2%

NYSE:NVO opened at $38.82 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The business’s 50-day simple moving average is $50.69 and its 200-day simple moving average is $52.02. Novo Nordisk A/S has a fifty-two week low of $35.85 and a fifty-two week high of $82.57. The stock has a market capitalization of $173.31 billion, a PE ratio of 11.19 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 52.74%.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Zacks Research upgraded Novo from “strong sell” to “hold,” which can temper selling pressure and signal some stabilization to investors. Zacks.com
• Positive Sentiment: New commercial channel: Novo ended its feud with Hims & Hers and agreed to sell Ozempic and Wegovy on the Hims platform — that broadens distribution and could recapture patients moving to compounded GLP‑1s. Novo and Hims & Hers become partners to end legal feud
• Positive Sentiment: WHO Foundation partnership: Novo committed roughly $8M to WHO Foundation initiatives on cardiorenal‑metabolic diseases, extending global health reach and supporting longer‑term reputation/market access in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Novo Holdings 2025 results: stable income and returns at the foundation level (DKK 21bn) provide context on group cash flows but are a second‑order signal for NVO’s near‑term share moves. Novo Holdings announces 2025 Annual Results
• Negative Sentiment: FDA warning letter over post‑marketing adverse event reporting for semaglutide (Ozempic/Wegovy) is the largest near‑term risk: regulators cited failures to follow reporting procedures, and coverage highlights linked deaths — this raises compliance risk and valuation uncertainty. FDA Warning Letter Puts Novo Nordisk Compliance And Valuation In Focus
• Negative Sentiment: Analyst pressure: TD Cowen and other brokers trimmed ratings/targets and coverage changes have driven intraday selling and downward revisions to near‑term expectations. Novo Nordisk A/S (NYSE:NVO) Stock Rating Lowered by TD Cowen
• Negative Sentiment: Legal/investor risk: a Pomerantz investigation and reports of trading down after analyst downgrades amplify litigation and sentiment risks that can pressure the share price. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO
• Negative Sentiment: Competitive and pipeline concerns: reports that rivals (notably Eli Lilly and other entrants) are expanding aggressively and that Novo’s pipeline may not blunt semaglutide LOE are longer‑term threats to growth and valuation. Novo Nordisk: Buying The Dip Before Volume Dominance

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.